Complete Filing Data
Barinthus Biotherapeutics plc. reported Stockholders Equity Including Portion Attributable To Noncontrolling Interest of $74.29 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Barinthus Biotherapeutics plc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$66.4M | -$61.1M | -$73.3M | $5.3M | -$50.9M | -$17.7M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $10.1M | -$2.5M | $10.2M | -$25.1M | -$7.2M | -$776.0K |
| Research And Development Expense | $25.6M | $42.2M | $44.9M | $42.4M | $20.4M | $14.4M |
| Operating Income Loss | -$70.6M | -$68.0M | -$83.9M | -$4.0M | -$45.2M | -$20.0M |
| Operating Expenses | $71.1M | $84.1M | $84.7M | $48.7M | $45.5M | $24.9M |
| Nonoperating Income Expense | $3.9M | $6.7M | $7.4M | $4.9M | -$5.9M | $2.2M |
| Net Income Loss Attributable To Noncontrolling Interest | -$30.0K | -$109.0K | -$100.0K | -$21.0K | -$247.0K | -$227.0K |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$56.3M | -$63.7M | -$63.3M | -$19.8M | -$58.4M | -$18.7M |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | -$22.0K | -$105.0K | -$94.0K | -$132.0K | -$250.0K | -$227.0K |
| Comprehensive Income Net Of Tax | -$56.3M | -$63.6M | -$63.2M | -$19.6M | -$58.1M | -$18.5M |
| Income Tax Expense Benefit | -$175.0K | -$44.0K | -$3.1M | -$4.5M | -$28.0K | $95.0K |
| Research And Development Incentive Income Expense | $2.0M | $4.0M | $3.5M | $1.2M | $4.0M | $3.3M |
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $15.0M | $802.0K | $44.7M | $268.0K | $4.8M |
| General And Administrative Expense | $40.8M | $29.7M | $39.8M | $6.4M | $25.1M | $10.5M |
| Other Nonoperating Income Expense | $16.0K | $135.0K | $1.1M | $567.0K | $332.0K | $42.0K |
| Research And Development Incentives Receivable | $1.1M | $7.1M | $4.9M | $4.5M | $6.2M | $2.7M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$66.6M | -$61.2M | -$76.5M | $850.0K | -$51.1M | |
| Deferred Income Tax Expense Benefit | -$175.0K | -$44.0K | -$3.1M | -$4.3M | -$119.0K | |
| Non Cash Interest Expense On Convertible Loan Notes | $51.0K | $48.0K | $28.0K | $19.0K | $813.0K | $3.6M |
| Interest Expense Nonoperating | $51.0K | $53.0K | $28.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$14.6M | -$21.1M | -$19.6M | -$8.1M | -$16.9M | -$15.5M | -$14.1M | -$23.8M | -$18.2M | $8.2M | $15.7M | $2.6M | -$4.6M | -$15.9M | -$15.3M | $158.0K | -$3.6M | -$3.8M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$2.9M | $8.3M | $4.6M | $9.2M | $164.0K | -$1.6M | -$7.8M | $5.6M | $4.6M | -$19.9M | -$16.8M | -$6.0M | -$6.5M | $86.0K | -$1.4M | $68.0K | -$144.0K | -$683.0K |
| Research And Development Expense | $5.4M | $8.0M | $8.3M | $11.1M | $11.7M | $11.1M | $15.1M | $13.5M | $9.8M | $9.7M | $9.7M | $10.7M | $4.4M | $4.5M | $4.6M | $3.7M | $3.9M | $4.2M |
| Operating Income Loss | -$15.1M | -$23.3M | -$20.6M | -$9.4M | -$18.3M | -$16.9M | -$16.1M | -$26.3M | -$21.5M | $7.2M | $13.2M | $654.0K | -$5.5M | -$16.8M | -$6.2M | -$1.4M | -$4.3M | -$4.6M |
| Operating Expenses | $15.2M | $23.3M | $20.9M | $24.6M | $18.9M | $17.1M | $16.1M | $26.7M | $22.0M | -$1.1M | $3.8M | $14.4M | $5.6M | $16.9M | $6.4M | $4.7M | $4.8M | $5.4M |
| Nonoperating Income Expense | $424.0K | $2.2M | $920.0K | $1.2M | $1.3M | $1.4M | $1.4M | $1.4M | $2.7M | $311.0K | $1.5M | $1.1M | $959.0K | $872.0K | -$9.3M | $1.6M | $679.0K | $698.0K |
| Net Income Loss Attributable To Noncontrolling Interest | -$5.0K | -$2.0K | -$10.0K | -$15.0K | -$12.0K | -$31.0K | -$38.0K | -$22.0K | -$43.0K | -$21.0K | -$4.0K | -$22.0K | -$13.0K | -$58.0K | -$118.0K | $42.0K | -$69.0K | -$130.0K |
| Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest | -$17.5M | -$12.8M | -$15.0M | $1.1M | -$16.8M | -$17.1M | -$21.9M | -$18.2M | -$13.6M | -$11.7M | -$1.1M | -$3.4M | -$11.0M | -$15.9M | -$16.8M | $268.0K | -$3.8M | -$4.6M |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | -$8.0K | $5.0K | -$7.0K | -$5.0K | -$11.0K | -$28.0K | -$48.0K | -$15.0K | -$37.0K | -$51.0K | -$34.0K | -$37.0K | -$25.0K | -$55.0K | -$114.0K | $49.0K | -$70.0K | -$148.0K |
| Comprehensive Income Net Of Tax | -$17.5M | -$12.8M | -$15.0M | $1.1M | -$16.8M | -$17.1M | -$21.9M | -$18.2M | -$13.6M | -$11.7M | -$1.1M | -$3.4M | -$11.0M | -$15.8M | -$16.7M | $219.0K | -$3.7M | -$4.5M |
| Income Tax Expense Benefit | -$71.0K | -$25.0K | -$22.0K | -$3.0K | -$7.0K | -$37.0K | -$603.0K | -$1.1M | -$516.0K | -$674.0K | -$915.0K | -$863.0K | -$7.0K | $12.0K | -$65.0K | |||
| Research And Development Incentive Income Expense | $240.0K | $1.3M | $302.0K | $608.0K | $693.0K | $594.0K | $1.2M | $559.0K | $1.2M | -$724.0K | $826.0K | $1.0M | $959.0K | $875.0K | $955.0K | $1.6M | ||
| Revenue From Contract With Customer Excluding Assessed Tax | $0.00 | $15.0M | $0.00 | $0.00 | $0.00 | $334.0K | $468.0K | $6.2M | $17.1M | $15.0M | $19.0K | $35.0K | $215.0K | $3.3M | $511.0K | $705.0K | ||
| General And Administrative Expense | $5.2M | $15.4M | $12.6M | $13.4M | $7.2M | $6.0M | $961.0K | $13.1M | $12.1M | $3.7M | $1.2M | $12.4M | $1.8M | $977.0K | $970.0K | $1.1M | ||
| Other Nonoperating Income Expense | -$275.0K | $320.0K | $75.0K | $26.0K | $20.0K | $0.00 | -$2.0K | $310.0K | $51.0K | -$3.0K | ||||||||
| Research And Development Incentives Receivable | $4.6M | $4.5M | $3.0M | $5.4M | $4.5M | $5.2M | $4.2M | $3.1M | $2.5M | $4.1M | $5.2M | $4.8M | $5.4M | $4.6M | $3.7M | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$14.6M | -$21.2M | -$19.7M | -$8.1M | -$17.0M | -$15.6M | -$14.7M | -$25.0M | -$18.7M | $7.5M | $14.8M | $1.7M | ||||||
| Deferred Income Tax Expense Benefit | -$22.0K | -$37.0K | -$516.0K | -$863.0K | -$25.0K | |||||||||||||
| Non Cash Interest Expense On Convertible Loan Notes | $12.0K | $12.0K | $0.00 | $813.0K | ||||||||||||||
| Interest Expense Nonoperating | $13.0K | $12.0K | $13.0K | $17.0K | $12.0K | $12.0K | $7.0K | $14.0K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $74.2M | $130.0M | $186.8M | $242.9M | $252.1M | -$36.9M | -$22.1M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $71.9M | $112.4M | $142.1M | $194.4M | $214.1M | $43.3M | $11.4M |
| Accrued Liabilities And Other Liabilities Current | $6.2M | $9.5M | $9.2M | $8.1M | $7.9M | $2.5M | |
| Retained Earnings Accumulated Deficit | -$304.1M | -$237.7M | -$176.6M | -$103.2M | -$108.6M | -$57.7M | |
| Property Plant And Equipment Net | $3.5M | $7.4M | $11.8M | $8.0M | $1.8M | $629.0K | |
| Prepaid Expense And Other Assets Current | $4.8M | $6.2M | $9.9M | $8.3M | $6.5M | $1.4M | |
| Operating Lease Right Of Use Asset | $1.6M | $4.4M | $7.6M | $7.8M | $7.3M | $2.1M | |
| Operating Lease Liability Noncurrent | $9.3M | $10.1M | $11.2M | $8.3M | $6.5M | $1.5M | |
| Operating Lease Liability Current | $2.0M | $1.9M | $1.8M | $433.0K | $523.0K | $192.0K | |
| Minority Interest | $84.0K | $106.0K | $211.0K | $305.0K | $437.0K | $391.0K | |
| Liabilities Current | $10.0M | $15.7M | $12.6M | $12.2M | $11.2M | $7.6M | |
| Liabilities And Stockholders Equity | $98.2M | $160.3M | $214.5M | $270.2M | $280.7M | $50.7M | |
| Liabilities | $23.9M | $30.2M | $27.5M | $27.0M | $28.2M | $53.8M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$40.5M | -$29.7M | -$52.3M | -$19.7M | $170.8M | $31.8M | |
| Assets Current | $77.8M | $125.7M | $156.9M | $213.0M | $226.8M | $47.9M | |
| Assets | $98.2M | $160.3M | $214.5M | $270.2M | $280.7M | $50.7M | |
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | -$15.7M | -$25.9M | -$23.3M | -$33.5M | -$8.5M | -$1.2M | |
| Accounts Payable Current | $350.0K | $2.5M | $1.6M | $3.7M | $2.4M | $4.7M | |
| Common Stock Value | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $0.00 | |
| Other Assets | $930.0K | $881.0K | $882.0K | $976.0K | $804.0K | ||
| Cash And Cash Equivalents At Carrying Value | $70.5M | $110.7M | $142.1M | $194.4M | $214.1M | $43.3M | |
| Intangible Assets Net Excluding Goodwill | $14.3M | $21.9M | $25.1M | $28.3M | $31.4M | ||
| Business Combination Contingent Consideration Liability Noncurrent | $2.9M | $2.7M | $1.8M | $1.7M | $2.4M | ||
| Non Cash Lease Expenses | $3.3M | $1.4M | $1.3M | $1.2M | $338.0K | ||
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | $26.0K | $866.0K | $55.0K | -$73.0K | |||
| Other Liabilities Noncurrent | $1.5M | $1.4M | $1.3M | $965.0K | |||
| Goodwill | $0.00 | $12.2M | $12.2M | $12.6M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity * | $84.5M | $102.4M | $115.5M | $159.3M | $156.6M | $171.8M | $195.4M | $217.2M | $233.3M | $243.8M | $254.4M | $253.1M | $242.5M | $249.9M | -$52.8M | -$28.8M | -$29.2M | -$25.9M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $75.7M | $87.8M | $100.6M | $106.1M | $117.8M | $130.0M | $160.3M | $173.0M | $191.3M | $200.1M | $192.3M | $200.6M | $233.9M | $243.6M | $155.9M | $29.6M | $5.3M | $6.4M |
| Accrued Liabilities And Other Liabilities Current | $6.7M | $7.4M | $7.2M | $8.0M | $10.3M | $8.3M | $11.9M | $8.5M | $7.0M | $11.3M | $7.3M | $7.0M | $4.4M | $3.4M | $3.3M | |||
| Retained Earnings Accumulated Deficit | -$293.0M | -$278.4M | -$257.3M | -$217.1M | -$209.0M | -$192.1M | -$159.3M | -$145.2M | -$121.4M | -$82.1M | -$90.3M | -$106.0M | -$93.5M | -$88.9M | -$73.0M | |||
| Property Plant And Equipment Net | $4.5M | $4.5M | $6.2M | $10.7M | $11.0M | $11.5M | $12.3M | $13.7M | $12.7M | $6.8M | $7.0M | $4.6M | $1.0M | $1.0M | $1.0M | |||
| Prepaid Expense And Other Assets Current | $6.3M | $7.7M | $6.3M | $8.2M | $9.6M | $8.0M | $6.6M | $8.3M | $5.9M | $8.2M | $11.7M | $7.4M | $6.7M | $8.5M | $3.4M | |||
| Operating Lease Right Of Use Asset | $2.1M | $3.3M | $3.9M | $7.4M | $7.3M | $7.4M | $7.5M | $7.7M | $7.7M | $7.6M | $8.3M | $6.7M | $8.8M | $2.0M | $2.1M | |||
| Operating Lease Liability Noncurrent | $9.6M | $10.0M | $10.0M | $10.7M | $10.7M | $10.9M | $11.2M | $11.0M | $10.0M | $8.1M | $8.3M | $6.4M | $7.7M | $1.4M | $1.4M | |||
| Operating Lease Liability Current | $2.0M | $2.0M | $2.0M | $2.0M | $1.9M | $1.9M | $1.5M | $1.1M | $649.0K | $186.0K | $299.0K | $331.0K | $435.0K | $202.0K | $198.0K | |||
| Minority Interest | $96.0K | $104.0K | $99.0K | $167.0K | $172.0K | $183.0K | $205.0K | $253.0K | $268.0K | $315.0K | $366.0K | $400.0K | $493.0K | $518.0K | $277.0K | |||
| Liabilities Current | $10.8M | $12.7M | $12.0M | $15.1M | $15.6M | $12.8M | $18.6M | $12.1M | $12.0M | $14.0M | $12.2M | $16.5M | $6.4M | $8.5M | $8.7M | |||
| Liabilities And Stockholders Equity | $109.2M | $129.6M | $142.0M | $188.7M | $186.7M | $199.5M | $230.0M | $246.1M | $261.8M | $275.5M | $285.1M | $286.1M | $256.6M | $259.8M | $166.5M | |||
| Liabilities | $24.6M | $27.1M | $26.4M | $29.2M | $30.0M | $27.5M | $34.4M | $28.7M | $28.2M | $31.3M | $30.3M | $33.0M | $14.1M | $9.9M | $10.1M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | -$11.8M | -$12.1M | -$3.1M | -$13.5M | $112.7M | -$5.0M | ||||||||||||
| Assets Current | $86.8M | $100.4M | $109.9M | $134.7M | $131.9M | $143.1M | $171.1M | $184.8M | $200.7M | $218.6M | $226.3M | $230.8M | $246.0M | $256.7M | $163.4M | |||
| Assets | $109.2M | $129.6M | $142.0M | $188.7M | $186.7M | $199.5M | $230.0M | $246.1M | $261.8M | $275.5M | $285.1M | $286.1M | $256.6M | $259.8M | $166.5M | |||
| Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax | -$15.9M | -$12.9M | -$21.2M | -$15.6M | -$24.7M | -$24.9M | -$31.1M | -$23.3M | -$28.9M | -$51.1M | -$31.2M | -$14.5M | -$9.0M | -$2.6M | -$2.7M | |||
| Accounts Payable Current | $698.0K | $1.8M | $1.4M | $3.1M | $2.6M | $1.2M | $5.1M | $2.4M | $4.3M | $2.4M | $4.5M | $4.7M | $1.3M | $4.7M | $4.8M | |||
| Common Stock Value | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | ||||
| Other Assets | $929.0K | $944.0K | $902.0K | $926.0K | $886.0K | $885.0K | $1.1M | $1.0M | $1.0M | $847.0K | $902.0K | $788.0K | $719.0K | |||||
| Cash And Cash Equivalents At Carrying Value | $74.3M | $86.3M | $99.1M | $160.3M | $173.0M | $191.3M | $200.1M | $192.3M | $200.6M | $233.9M | $243.6M | $155.9M | ||||||
| Intangible Assets Net Excluding Goodwill | $14.9M | $20.4M | $21.2M | $22.7M | $23.5M | $24.3M | $25.9M | $26.7M | $27.5M | $29.1M | $29.9M | $30.6M | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | $2.5M | $2.5M | $2.7M | $1.6M | $1.9M | $1.9M | $1.8M | $2.1M | $1.7M | $2.8M | $2.7M | $2.4M | ||||||
| Non Cash Lease Expenses | $813.0K | $359.0K | $279.0K | $228.0K | ||||||||||||||
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | $1.0K | $60.0K | $85.0K | $317.0K | $626.0K | $143.0K | ||||||||||||
| Other Liabilities Noncurrent | $1.5M | $1.5M | $1.4M | $1.4M | $1.3M | $1.3M | $1.3M | $1.3M | $1.3M | $711.0K | $776.0K | $434.0K | ||||||
| Goodwill | $12.2M | $12.2M | $12.2M | $12.2M | $12.2M | $12.2M | $12.6M | $12.6M | $12.6M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $468.0K | $4.7M | $5.1M | $9.9M | $16.5M | $3.6M |
| Payments To Acquire Property Plant And Equipment | $37.0K | $892.0K | $5.4M | $6.1M | $1.1M | $293.0K |
| Net Cash Provided By Used In Operating Activities | -$48.0M | -$28.9M | -$50.9M | -$14.4M | -$32.6M | -$11.0M |
| Net Cash Provided By Used In Investing Activities | $416.0K | -$892.0K | -$5.4M | -$5.8M | -$12.9M | -$293.0K |
| Increase Decrease In Research And Development Incentives Receivable | -$6.4M | $2.3M | $127.0K | -$1.2M | $3.6M | -$295.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$1.7M | -$3.6M | -$2.2M | $2.2M | $4.2M | $435.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$3.8M | $456.0K | $2.0M | $751.0K | $4.4M | $1.0M |
| Increase Decrease In Accounts Payable | -$2.2M | $898.0K | -$3.4M | $1.1M | -$3.5M | $586.0K |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $7.0M | -$2.0M | $2.2M | $187.0K | -$6.5M | $1.7M |
| Depreciation Depletion And Amortization | $5.8M | $5.8M | $5.4M | $4.3M | $602.0K | $208.0K |
| Net Cash Provided By Used In Financing Activities | $2.0K | $2.2M | $1.9M | $325.0K | $222.7M | $41.4M |
| Increase Decrease In Accounts Receivable | $0.00 | -$5.8M | $5.8M | -$559.0K | -$479.0K | |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 2.0K | 0.00 | 0.00 | 0.00 | 9.0K | |
| Proceeds From Issuance Of Common Stock | $0.00 | $2.2M | $2.0M | $484.0K | $102.8M | |
| Increase Decrease In Other Operating Assets | $0.00 | -$128.0K | $387.0K | $735.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $468.0K | $1.6M | $2.2M | $4.0M | $797.0K | $856.0K |
| Payments To Acquire Property Plant And Equipment | $5.0K | $308.0K | $2.5M | $1.1M | $392.0K | $22.0K |
| Net Cash Provided By Used In Operating Activities | -$14.9M | -$11.8M | -$3.2M | -$6.6M | -$8.0M | -$4.3M |
| Net Cash Provided By Used In Investing Activities | -$5.0K | -$308.0K | -$2.5M | -$1.1M | -$392.0K | -$22.0K |
| Increase Decrease In Research And Development Incentives Receivable | -$4.2M | $331.0K | -$2.1M | -$1.3M | $955.0K | $680.0K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | -$48.0K | -$1.9M | -$4.1M | $1.1M | $393.0K | $153.0K |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$2.5M | -$823.0K | -$1.3M | $2.8M | -$108.0K | $343.0K |
| Increase Decrease In Accounts Payable | -$1.2M | -$524.0K | -$1.7M | $1.7M | -$707.0K | -$1.2M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $3.1M | -$492.0K | $935.0K | -$5.6M | -$785.0K | -$655.0K |
| Depreciation Depletion And Amortization | $2.0M | $1.4M | $1.2M | $966.0K | $92.0K | $49.0K |
| Net Cash Provided By Used In Financing Activities | $2.0K | $503.0K | $1.7M | -$159.0K | $121.8M | |
| Increase Decrease In Accounts Receivable | $0.00 | -$5.0M | $18.4M | -$208.0K | -$524.0K | |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 2.0K | 0.00 | 0.00 | 0.00 | ||
| Proceeds From Issuance Of Common Stock | $0.00 | $503.0K | $1.8M | |||
| Increase Decrease In Other Operating Assets | $0.00 | -$123.0K | $4.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Diluted EPS * | -$1.64 | -$1.55 | -$1.91 | $0.14 | -$1.96 | -$2.24 |
| Weighted Average Number Of Shares Outstanding Basic | 40.5M | 39.3M | 38.4M | 37.2M | 25.9M | 7.9M |
| Weighted Average Number Of Diluted Shares Outstanding | 40.5M | 39.3M | 38.4M | 38.2M | 25.9M | 7.9M |
| Earnings Per Share Basic | $-1.64 | $-1.55 | $-1.91 | $0.14 | $-1.96 | $-2.24 |
| Common Stock Shares Outstanding | 40.8M | 40.2M | 38.6M | 37.7M | 37.2M | 8.0M |
| Common Stock Shares Issued | 40.8M | 40.2M | 38.6M | 37.7M | 37.2M | 8.0M |
| Common Stock Shares Authorized | 40.8M | 40.2M | 38.6M | 37.7M | 37.2M | 8.0M |
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$0.36 | -$0.52 | -$0.49 | -$0.21 | -$0.43 | -$0.40 | -$0.37 | -$0.62 | -$0.48 | $0.22 | $0.41 | $0.07 | -$0.13 | -$0.64 | -$1.90 | $0.01 | -$0.45 | -$0.49 |
| Weighted Average Number Of Shares Outstanding Basic | 40.7M | 40.3M | 40.3M | 39.4M | 39.0M | 38.8M | 38.5M | 38.4M | 38.0M | 37.2M | 37.2M | 37.2M | 34.8M | 24.9M | 8.1M | 7.9M | ||
| Weighted Average Number Of Diluted Shares Outstanding | 40.7M | 40.3M | 40.3M | 39.4M | 39.0M | 38.8M | 38.5M | 38.4M | 38.0M | 38.2M | 38.2M | 38.3M | 34.8M | 24.9M | 8.1M | 15.9M | ||
| Earnings Per Share Basic | $-0.36 | $-0.52 | $-0.49 | $-0.21 | $-0.43 | $-0.40 | $-0.37 | $-0.62 | $-0.48 | $0.22 | $0.42 | $0.07 | $-0.13 | $-0.64 | $-1.90 | $0.02 | ||
| Common Stock Shares Outstanding | 40.8M | 40.3M | 40.3M | 39.5M | 39.2M | 39.0M | 38.5M | 38.5M | 38.4M | 37.3M | 37.2M | 37.2M | 34.3M | 34.3M | 8.2M | |||
| Common Stock Shares Issued | 40.8M | 40.3M | 40.3M | 39.5M | 39.2M | 39.0M | 38.5M | 38.5M | 38.4M | 37.3M | 37.2M | 37.2M | 34.3M | 34.3M | 8.2M | |||
| Common Stock Shares Authorized | 40.8M | 40.3M | 40.3M | 39.5M | 39.2M | 39.0M | 38.5M | 38.5M | 38.4M | 37.3M | 37.2M | 37.2M | 34.3M | 34.3M | 8.2M | |||
| Common Stock Par Or Stated Value Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $468.0K | $4.7M | $5.1M | $9.9M | $16.5M | |
| Investment Income Interest | $2.0M | $2.7M | $2.9M | $3.1M | $2.0K | $0.00 |
| Additional Paid In Capital | $393.9M | $393.5M | $386.6M | $379.5M | $369.1M | $21.7M |
| Stock Issued During Period Value New Issues | $2.0K | $2.2M | $2.0M | $102.8M | ||
| Foreign Currency Transaction Gain Loss Unrealized | -$3.7M | $649.0K | -$7.5M | $24.9M | $209.0K | $448.0K |
| Stock Issued During Period Value Other | $2.0M | $484.0K | $9.0K | |||
| Other Operating Income | $506.0K | $1.2M | $0.00 | |||
| Capital Expenditures Incurred But Not Yet Paid | $0.00 | $87.0K | $559.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | Q2 2022 | Q1 2022 | Q3 2021 | Q2 2021 | Q1 2021 | Q3 2020 | Q2 2020 | Q1 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | -$415.0K | -$281.0K | $468.0K | $1.1M | $1.2M | $1.6M | $57.0K | $2.0M | $2.2M | $1.1M | $2.7M | $4.0M | $3.4M | $8.7M | $797.0K | $154.0K | $415.0K | $856.0K |
| Investment Income Interest | $472.0K | $523.0K | $556.0K | $631.0K | $635.0K | $775.0K | $196.0K | $522.0K | $1.6M | $1.0M | $669.0K | $83.0K | $2.0K | |||||
| Additional Paid In Capital | $393.2M | $393.7M | $393.9M | $391.9M | $390.3M | $388.7M | $385.7M | $385.6M | $383.5M | $376.9M | $375.8M | $373.1M | $344.4M | $340.8M | $22.5M | |||
| Stock Issued During Period Value New Issues | $0.00 | $0.00 | $2.0K | $465.0K | $358.0K | $503.0K | $14.0K | $123.0K | $1.8M | $0.00 | $102.8M | $0.00 | $0.00 | |||||
| Foreign Currency Transaction Gain Loss Unrealized | -$1.6M | $1.0M | -$3.5M | $209.0K | $982.0K | |||||||||||||
| Stock Issued During Period Value Other | $14.0K | $123.0K | $1.8M | $0.00 | $0.00 | $0.00 | $0.00 | |||||||||||
| Other Operating Income | $156.0K | $13.0K | $329.0K | $210.0K | $577.0K | $205.0K | $0.00 | $0.00 | $0.00 | |||||||||
| Capital Expenditures Incurred But Not Yet Paid | $0.00 | $95.0K | $2.2M | $1.4M | $67.0K |
Most recent annual filing with the SEC: March 13, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.